RecruitingPhase 1NCT06530966
Phase I Study of ICP-332 in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-332 in Healthy Subjects
Sponsor
InnoCare Pharma Inc.
Enrollment
24 participants
Start Date
Jul 23, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
A multiple ascending dose phase I study of ICP-332 in healthy subjects
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria3
- Voluntarily sign the informed consent form
- Body mass index (BMI) of ≥ 18.5 kg/m2 and < 30 kg/m2
- Male or infertile female subjects who are between 18-55 years old (inclusive)
Exclusion Criteria4
- Significant current or past acute or chronic disease or condition.
- A history of tuberculosis or current active/latent infection.
- With a history of drug or food allergy, or allergy to any of the composition components of the study drug, or allergic disease.
- Subjects with clinically significant abnormalities in the screening examinations.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGICP-332 Tablets
Eligible patients will receive ICP-332 tablets orally as per the protocol
DRUGICP-332 Placebo Tablets
Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06530966
Related Trials
Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes
NCT074157592 locations
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
NCT015686971 location
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061
NCT072419101 location
Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
NCT074701251 location
Radiocaine Safety Study
NCT070812171 location